Vaccination proposal for patients on onasemnogene abeparvovec therapy

Eur J Paediatr Neurol. 2024 Mar:49:95-99. doi: 10.1016/j.ejpn.2024.02.010. Epub 2024 Mar 1.

Abstract

The approval of disease-modifying treatment in spinal muscular atrophy made the condition less severe. The course of the disease changed, but some new concerns occurred with the different new therapies. The side effects of onasemnogene aboparvovec therapy can raise differential diagnostic challenges and necessitate immune therapy, leading to immunosuppression affecting response to vaccines. We provide a pretherapy screening proposal from an infectological point of view separately for newborns treated presymptomatically and children diagnosed with symptoms at any age. Furthermore, we summarise the guidelines on the vaccination before, during, and after immune therapy (steroids) in onasemnogene aboparvovec-treated patients.

Keywords: Elevated transaminase; Onasemnogene abeparvovec; Spinal muscular atrophy; Vaccination.

Publication types

  • Review

MeSH terms

  • Biological Products / adverse effects
  • Biological Products / therapeutic use
  • Child
  • Humans
  • Infant
  • Infant, Newborn
  • Recombinant Fusion Proteins*
  • Spinal Muscular Atrophies of Childhood / drug therapy
  • Vaccination* / adverse effects

Substances

  • Zolgensma
  • Biological Products
  • Recombinant Fusion Proteins